Vanda Pharmaceuticals appoints Dr. Charles Duncan to Board of Directors effective April 22, 2026

Vanda Pharmaceuticals Inc.

Board expands from six to seven members; Duncan appointed as Class II director with term ending at 2026 annual meeting.
Initial RSU award of $390,000 vests quarterly over four years; annual cash retainer of $50,000.
Additional annual RSU award of $260,000 after each annual meeting starting 2026, vesting one year later.
Duncan previously Managing Director at Cantor Fitzgerald, covering >70 biotech companies; founded Sulci Advisors in Sep 2025.
Duncan cites recent approvals of NEREUS and BYSANTI, label expansion for Fanapt, and pipeline catalysts over next 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.